Dr. Omid C. Farokhzad

The article Forbes salutes nanoparticle chemotherapy said

Forbes has highlighted the important role of nanotechnology in driving forward the pharmaceutical industry with three of their top five nanotech breakthroughs in 2006 having biological applications.
 
Speaking to Drugresearcher.com, Dr Omid Farokhzad from Harvard University, US, said: “Our targeted nanoparticles are designed and engineered to differentiate tumor cells from normal cells and once inside the cancer cell, to release their chemotherapy payload.
 
“We are able to get a substantially higher dose inside the cancer cell but actually using a much lower overall dose.”

Omid C. Farokhzad, M.D. is Associate Professor at Harvard Medical School (HMS) and a physician-scientist in the Department of Anesthesiology at Brigham and Women’s Hospital (BWH).
 
Omid is a cofounder of BIND Biosciences, a biopharmaceutical company developing targeted nanoparticle therapeutics; and Selecta Biosciences, a biopharmaceutical company developing immunomodulatory therapeutics and prophylactic vaccines. He serves as Director on the board of BIND and as Director and Vice Chairman on the board of Selecta.
 
His research group is focused on developing novel nanotechnologies for medical applications. He has pioneered the application of micro- and nanotechnology for high throughput development and screening of targeted drug delivery systems for a myriad of clinical applications.
 
Omid was named among the Nano50 winners of 2007 by Nanotech Briefs which awards the most innovative people and design ideas that will revolutionize nanotechnology. He completed his post-doctoral clinical and research trainings, respectively, at the BWH/HMS and MIT in the laboratory of Dr. Robert Langer. He has authored more than 50 papers and is an inventor of more than 40 pending patents. He earned his M.D. and M.A. from Boston University School of Medicine.
 
He coauthored Impact of nanotechnology on drug delivery, Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo, Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer, Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles, Nanotechnology for drug delivery: the perfect partnership, Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy, HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy, Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups, Factors affecting the clearance and biodistribution of polymeric nanoparticles, Microfluidic platform for controlled synthesis of polymeric nanoparticles, Nanocarriers as an emerging platform for cancer therapy, Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers, Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates, and An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform.
 
Read his LinkedIn profile.